You can buy or sell Codexis and other stocks, options, ETFs, and crypto commission-free!
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. Read More The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Yahoo FinanceMay 16
Who Has Been Selling Codexis, Inc. Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at whether insiders have been buying or selling shares in Codexis, Inc. (NASDAQ:CDXS). What Is Insider Selling? Scroll to continue with content Ad It's quite normal to see company insiders, such as board members, trading in company stock, from time to...
BRIEF-Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis
May 15 (Reuters) - Codexis Inc: * CODEXIS INC - ANNOUNCES SIGNING OF A CODEEVOLVER PLATFORM AGREEMENT WITH NOVARTIS * CODEXIS - UNDER TERMS, NOVARTIS WILL PAY CO UPFRONT PAYMENT, MILESTONE PAYMENTS UPON SATISFACTORY COMPLETION OF TECHNOLOGY TRANSFER * CODEXIS - WILL BE ELIGIBLE TO GET PAYMENTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS MADE WITH ENZYMES DEVELOPED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY * CODEXIS INC - RECEIVES CERTAIN RIGHTS FOR FUTURE PURCHASES OF ENZYMES DEVELOPED & SOURCED BY NOVARTIS US...
Yahoo FinanceMay 15
Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader
Third CodeEvolver® licensing agreement with a major pharma company REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary CodeEvolver® protein engineering platform technology to Novartis to develop novel performance enzymes for use in manufacturing pharmaceutical products. Upon ...
Expected Aug 7, After Hours